Subsequent clinical trials have confirmed that targeted inhibition of the PD-1/PD-L1 signaling pathway can continuously activate anti-tumor immune response, inhibit tumor growth, and reduce the disease burden of patients. This evidence concerns the gene PDCD1 and neoplasm.